2010 Kancera Ab
Karolinska Institutet Science Park, Banvaktsvägen
About KanceraKancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of leukemia and solid tumors, by regulating the immune system, blocking survival signals in the cancer cell and on addressing cancer metabolism. Kancera’s operations are based in the Karolinska Institutet Science Park in Stockholm and the company employs around 18 people. Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7500 as of June 30th, 2017. FNCA is Kancera’s Certified Adviser. Professor Carl-Henrik Heldin, Professor Håkan Mellstedt, and MD PhD Charlotte Edenius are board members and Kancera´s scientific advisers.
CEO: Thomas Olin
8 articles with Kancera
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
Thomas Olin, chief executive officer of Kancera, took time to discuss the company, the Fracktalkine pathway and the upcoming clinical trial.
5/26/2020Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
5/21/2020Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
12/5/2019Companies from across the globe provide updates on their business and pipelines.
9/5/2019Companies from across Europe and Asia share updates on their business and pipelines.
Kancera AB is seeing encouraging results from its Phase 1 study with its Lead Immunoregulating Drug Candidate KAND567.